BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bioinformatics Software | QIAGEN Digital Insights - ECPv6.15.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bioinformatics Software | QIAGEN Digital Insights
X-ORIGINAL-URL:https://staging.digitalinsights.supremeclients.com
X-WR-CALDESC:Events for Bioinformatics Software | QIAGEN Digital Insights
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231003T130000
DTEND;TZID=Europe/Paris:20231003T140000
DTSTAMP:20260410T234053
CREATED:20230912T162604Z
LAST-MODIFIED:20241024T182937Z
UID:10000681-1696338000-1696341600@staging.digitalinsights.supremeclients.com
SUMMARY:Supercharge your AI in drug discovery with high-quality biomedical data
DESCRIPTION:If you’re working in pharma or biotech\, you likely rely on artificial intelligence (AI) to help you identify new drug targets or plausible biomarkers for disease within large data sets. Yet AI alone isn't enough. A large proportion of Biomedical data have errors and are unstructured. For AI models to provide reliable insights\, the underlying data must be of ‘high quality’\, meaning it’s accurate\, comprehensive\, up-to-date and standardized. \nJesper Ryge (Idorsia Pharmaceuticals)\, Alex Jarasch (Neo4j) and Venkatesh Moktali (QIAGEN Digital Insights) come together to showcase the practical applications of high-quality biomedical relationships data from the QIAGEN Biomedical Knowledge Base (BKB) to accelerate\, improve and transform research in drug discovery and pharmaceutical development. By applying AI to a gene-disease knowledge graph\, they identify promising drug targets and key mechanisms underlying diseases. A brief introduction to Neo4j shows how graph-centric analysis and visualizations facilitate the effective exploration of large knowledge graphs like BKB. This integration of high-quality curated data\, AI-driven analysis and advanced visualization provides valuable insights and accelerates the progress of precision medicine. \nIn this webinar\, you’ll learn how you can: \n\nBuild disease interactomes using protein-protein interactions\nIdentify high-quality drug targets using inferred causal interactions\nChoose targets with the least likelihood of adverse outcomes by leveraging the depth of the data in BKB\nFormulate plausible hypotheses using state-of-the-art graph visualization\n\nDon't miss this chance to learn how to supercharge your AI toolbox to transform your drug discovery.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/supercharge-your-ai-in-drug-discovery-with-high-quality-biomedical-data/
LOCATION:Virtual - EMEA - CET
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1212_7_QDI_QDI_BKB_Original_59173.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231003T130000
DTEND;TZID=America/New_York:20231003T140000
DTSTAMP:20260410T234053
CREATED:20230912T162824Z
LAST-MODIFIED:20241024T182937Z
UID:10000682-1696338000-1696341600@staging.digitalinsights.supremeclients.com
SUMMARY:Supercharge your AI in drug discovery with high-quality biomedical data
DESCRIPTION:If you’re working in pharma or biotech\, you likely rely on artificial intelligence (AI) to help you identify new drug targets or plausible biomarkers for disease within large data sets. Yet AI alone isn't enough. A large proportion of Biomedical data have errors and are unstructured. For AI models to provide reliable insights\, the underlying data must be of ‘high quality’\, meaning it’s accurate\, comprehensive\, up-to-date and standardized. \nJesper Ryge (Idorsia Pharmaceuticals)\, Alex Jarasch (Neo4j) and Venkatesh Moktali (QIAGEN Digital Insights) come together to showcase the practical applications of high-quality biomedical relationships data from the QIAGEN Biomedical Knowledge Base (BKB) to accelerate\, improve and transform research in drug discovery and pharmaceutical development. By applying AI to a gene-disease knowledge graph\, they identify promising drug targets and key mechanisms underlying diseases. A brief introduction to Neo4j shows how graph-centric analysis and visualizations facilitate the effective exploration of large knowledge graphs like BKB. This integration of high-quality curated data\, AI-driven analysis and advanced visualization provides valuable insights and accelerates the progress of precision medicine. \nIn this webinar\, you’ll learn how you can: \n\nBuild disease interactomes using protein-protein interactions\nIdentify high-quality drug targets using inferred causal interactions\nChoose targets with the least likelihood of adverse outcomes by leveraging the depth of the data in BKB\nFormulate plausible hypotheses using state-of-the-art graph visualization\n\nDon't miss this chance to learn how to supercharge your AI toolbox to transform your drug discovery.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/supercharge-your-ai-in-drug-discovery-with-high-quality-biomedical-data-2/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1212_7_QDI_QDI_BKB_Original_59173.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Kolkata:20231004T110000
DTEND;TZID=Asia/Kolkata:20231004T120000
DTSTAMP:20260410T234053
CREATED:20230814T163214Z
LAST-MODIFIED:20241024T182922Z
UID:10000663-1696417200-1696420800@staging.digitalinsights.supremeclients.com
SUMMARY:Introduction to QIAGEN CLC Genomics Workbench & Getting Started
DESCRIPTION:In this training\, we will introduce you to QIAGEN CLC Genomics Workbench\, including a live demo of the basic features and main functionalities.\nDuring the training\, we’ll cover:\n• A general overview of the Workbench user interface\n• Easy installation on Windows\, Mac and Linux\n• Plugin installation\, e.g.\, Biomedical Genomics Analysis plugin\n• Reference Data Management\n• Working with reads from various NGS platforms\n• Running individual tools and workflows\n• Batch processing of data\n• Data visualization using Track List/Genome Browser\n• How to export of data and share workflows\n• Q&A
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/introduction-to-qiagen-clc-genomics-workbench-getting-started/
LOCATION:Virtual - India\, India
CATEGORIES:Discovery,Training
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1040_9_QDI_ICLC_GWBv21_Gi1223402761_16x9_Large-1200px_53601.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231004T130000
DTEND;TZID=America/New_York:20231004T150000
DTSTAMP:20260410T234053
CREATED:20230912T140635Z
LAST-MODIFIED:20241024T182931Z
UID:10000672-1696424400-1696431600@staging.digitalinsights.supremeclients.com
SUMMARY:New user training: Large dataset analysis and knowledge base queries using QIAGEN Ingenuity Pathway Analysis (IPA)
DESCRIPTION:Join us for a 120-minute training session for new users of QIAGEN IPA. \nIn this training\, you’ll learn how to:\n• Upload your dataset (RNA-seq\, scRNA-seq\, proteomics\, metabolomics and more) and perform interactive core/pathway analysis in IPA\n• Understand the different result types produced (pathways\, key regulators\, impact on biological functions/diseases and more)\n• Compare different experimental conditions (treatments\, time points\, single-cell clusters\, disease types and more) and identify similarities and contrasts\n• Generate a network even without a dataset or experimental design for hypothesis generation \nFor those with IPA license\,\nTo install IPA before or after this training\, please use below installer.\nhttps://qiagen.showpad.com/share/CBv30blCPKFDUYHRWtAvI
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/new-user-training-large-dataset-analysis-and-knowledge-base-queries-using-qiagen-ingenuity-pathway-analysis-ipa-4/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Training
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/BannerAd1_FAS_400x300.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231005T100000
DTEND;TZID=America/New_York:20231005T110000
DTSTAMP:20260410T234053
CREATED:20230912T163515Z
LAST-MODIFIED:20241024T182938Z
UID:10000683-1696500000-1696503600@staging.digitalinsights.supremeclients.com
SUMMARY:Circulating Tumor Cell Detection and Analysis to Support Malignancy Designation\, Tumor-of-Origin Identification\, and Treatment Selection
DESCRIPTION:Circulating tumor cells (CTCs) are cells that leave the primary tumor and are intravasated into the blood circulation system. A subset of those make it to other organs and are responsible for metastasis. iCellate’s CellMate platform is a CTC-based liquid biopsy for cancer cell enrichment\, detection\, and biomarker analysis via a simple blood draw. \nIn this seminar\, you’ll learn: \n\nFrom Helena Silva Cascales\, senior scientist at iCellate Medical AB\, how the isolation of whole-tumor cells provides a more comprehensive biomarker analysis\, including genomic sequencing and multiplexed protein expression analysis.\nFrom Kashyap Dave\, principal scientist at iCellate Medical AB\, how DNA from single CTCs can be amplified\, sequenced\, and analyzed to support malignancy designation and tissue of origin identification using classification analyses under development within Qiagen CLC Genomics Workbench.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/circulating-tumor-cell-detection-and-analysis-to-support-malignancy-designation-tumor-of-origin-identification-and-treatment-selection/
LOCATION:Virtual - Americas - EST\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20231005T110000
DTEND;TZID=UTC:20231005T120000
DTSTAMP:20260410T234053
CREATED:20230912T142145Z
LAST-MODIFIED:20241024T182931Z
UID:10000673-1696503600-1696507200@staging.digitalinsights.supremeclients.com
SUMMARY:Scale up NGS bioinformatics analysis throughput with QIAGEN CLC Genomics cloud computing
DESCRIPTION:Scale your NGS analysis to match your sequencing throughput using our QIAGEN CLC Genomics cloud solution. In this webinar\, you’ll learn about the flexible and powerful setup for running your NGS sequence analyses on Amazon Web Services (AWS). You’ll learn how to use QIAGEN CLC Genomics Workbench to customize workflows and send analyses to AWS Batch for execution. Together we’ll also explore analysis automation solutions\, third-party dockers\, audit trails and user management\, all of which are available with QIAGEN CLC Genomics Server software. \nTogether\, we’ll explore how to:\n• Customize template workflows to meet your NGS analysis requirements\n• Set up a QIAGEN CLC Genomics cloud environment on AWS\n• Submit workflows to run on AWS and to retrieve results from these analyses.\n• Use third-party dockers and automate workflow execution
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/scale-up-ngs-bioinformatics-analysis-throughput-with-qiagen-clc-genomics-cloud-computing/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1108_8_QDI_CLC_Challenger_Or54963_16x9_56810_Large-1200px-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20231010T110000
DTEND;TZID=UTC:20231010T120000
DTSTAMP:20260410T234053
CREATED:20230912T143148Z
LAST-MODIFIED:20241024T182932Z
UID:10000674-1696935600-1696939200@staging.digitalinsights.supremeclients.com
SUMMARY:QIAGEN Biomedical Knowledge Base: Data- and analytics-driven drug discovery
DESCRIPTION:Biomedical relationships knowledge is now required for innovative data- and analytics-driven drug discovery. It powers biomedical knowledge graph analysis\, artificial intelligence (AI)-driven target identification and many more applications.\nIn this one-hour training\, you’ll get an introduction to QIAGEN Biomedical Knowledge Base. You’ll learn how to tackle applications you can’t achieve with the QIAGEN Ingenuity Pathway Analysis (IPA) graphical user interface\, or which can be done quicker and with more flexibility when performed programmatically. You’ll learn how to perform queries such as:\n• Quickly find the shortest connections between genes/proteins/metabolites of interest in the context of a specific disease \n• Systematically build a network using a short list of genes/proteins/metabolites/chemicals\n• Recreate a drug mechanism of action \nPlease note: Based on the feedback we receive from you\, the registrants\, we may modify the topics we cover to ensure we discuss material that’s most relevant to you.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/qiagen-biomedical-knowledge-base-data-and-analytics-driven-drug-discovery/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1212_9_QDI_QDI_BKB_Original_61828_16x9_62947_Large-1200px.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20231012T100000
DTEND;TZID=UTC:20231012T120000
DTSTAMP:20260410T234053
CREATED:20230912T164947Z
LAST-MODIFIED:20241024T182938Z
UID:10000685-1697104800-1697112000@staging.digitalinsights.supremeclients.com
SUMMARY:Part 1: AI-Powered Hereditary Disease Diagnostics: Closing the Gap in Clinical Exome Completeness
DESCRIPTION:Clinical exome sequencing (CES) is increasingly being adopted by small and mid-sized laboratories to diagnose genetic diseases\, aid treatment decisions\, and provide prognostic information. However\, the exponential increase in genetic data generated from exome and genome panels poses significant workflow challenges. The ability to prioritize potentially pathogenic variants from large datasets and identify the few candidate variants becomes more difficult. This issue is further amplified in cases where labs must use deep phenotyping of patients and compare that to reference genotype-phenotype knowledge associated with each candidate variant. To overcome these challenges\, labs are beginning to implement Artificial Intelligence (AI) in their variant analysis\, interpretation and reporting workflows. \nJoin us for our 2023 Clinical Hereditary Disease Diagnostics Summit\, a free-to-attend\, two-part event exploring the opportunities and limitations of AI in hereditary disease diagnostics. Designed to help clinical diagnostic labs learn how to safely apply AI to exome and genome sequencing workflows\, the content-rich event will feature invited lectures from lab directors and clinical geneticists\, thought-provoking discussions on the future of hereditary disease diagnostics\, as well as educational presentations on the latest databases and AI-powered software for germline secondary and tertiary analysis. \nPart I: Educational talks – October 12\, 2023 \nAn education session exploring the latest databases\, software\, and services for germline secondary and tertiary NGS analysis. Topics will include: \n\nHow labs can achieve clinical exome completeness with AI-enriched and manually curated content\nHow labs can apply enhanced phenotype-driven ranking in clinical cases\nHow labs can safely use a “smart” approach to AI to reach the best possible chance of reaching a diagnosis
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/part-1-ai-powered-hereditary-disease-diagnostics-closing-the-gap-in-clinical-exome-completeness/
LOCATION:Virtual Global Event (Times shown in EST)
CATEGORIES:Clinical,Training
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1325_0_QDI_QCI_HGMD_blog_Gi1346512014.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231012T130000
DTEND;TZID=America/New_York:20231012T143000
DTSTAMP:20260410T234053
CREATED:20230912T144219Z
LAST-MODIFIED:20241024T182932Z
UID:10000675-1697115600-1697121000@staging.digitalinsights.supremeclients.com
SUMMARY:Exploring pan-cancer immunomodulators for biomarker discovery and validation using TCGA and public single-cell data
DESCRIPTION:Cancer outcome is influenced by both the tumor microenvironment and host immune response. Using QIAGEN OmicSoft Studio to access public data from The Cancer Genome Atlas (TCGA) and our human Single Cell Lands collection\, you’ll learn how to:\n• View host immune response clusters across TCGA samples\n• Identify differentially expressed immunomodulators across sample groups\n• Visualize single-cell dimension reduction maps and overlay expression data\n• Identify potential biomarkers whose expression correlates or anti-correlates with target genes\n• Validate new biomarkers using custom queries and TCGA survival data
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/exploring-pan-cancer-immunomodulators-for-biomarker-discovery-and-validation-using-tcga-and-public-single-cell-data/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_9308_BIOX_OmicSoft_Gi576919878_V2_Large-1200px_47746.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231017T090000
DTEND;TZID=Europe/Paris:20231017T100000
DTSTAMP:20260410T234053
CREATED:20231011T152914Z
LAST-MODIFIED:20241024T182942Z
UID:10000690-1697533200-1697536800@staging.digitalinsights.supremeclients.com
SUMMARY:Integrating deeply curated omics data with APIs for biomarkers and drug-target investigation
DESCRIPTION:This webinar is for data scientists and bioinformaticians working in biopharma who need extensive high-quality omics data for target discovery efforts. Learn how to programmatically discover\, retrieve\, filter\, aggregate\, and analyze omics data from QIAGEN’s extensive repositories of deeply-curated multi-omics data. Attendees will learn how to leverage extensive metadata to find and combine datasets of interest\, find and test signatures\, and perform custom analyses to reveal patterns relevant to disease. Join us to learn how QIAGEN OmicSoft Lands API can revolutionize your data analysis workflows and help you make more informed decisions.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/integrating-deeply-curated-omics-data-with-apis-for-biomarkers-and-drug-target-investigation-2/
LOCATION:Virtual - EMEA - CET
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1059_9_QDI_OncoLand_028824_Large-1200px_54664.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231017T130000
DTEND;TZID=America/New_York:20231017T150000
DTSTAMP:20260410T234053
CREATED:20230912T153140Z
LAST-MODIFIED:20241024T182933Z
UID:10000676-1697547600-1697554800@staging.digitalinsights.supremeclients.com
SUMMARY:RNA-seq data analysis and interpretation using QIAGEN CLC and QIAGEN IPA
DESCRIPTION:This 120-minute training will teach you how to easily analyze and interpret RNA-seq data using QIAGEN CLC Genomics Workbench software and QIAGEN Ingenuity Pathway Analysis (IPA). \nFor RNA-seq data\, you will learn how to:\n• Import FASTQ files\, cell matrix files and metadata and how to download references\n• Map reads to a reference genome and generate gene and transcript counts and QC reports displaying % mapped reads\, knee plots\, etc.\n• Generate visualizations of results\, such as heatmaps\, differential expression tables\, PCA/PCOA plots\, Venn diagrams and others\n• Easily customize RNA-seq workflows\n• Export publication-quality graphics\, tables and reports\n• Send differential expression tables to QIAGEN Ingenuity Pathway Analysis directly from QIAGEN CLC Genomics Workbench to analyze and interpret relevant pathways \nExplore the types of analyses and visualizations you’ll learn to generate (slides from previous training): https://qiagen.showpad.com/share/qiZLmCUS32GZNM1B4llMf
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/rna-seq-data-analysis-and-interpretation-using-qiagen-clc-and-qiagen-ipa-2/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Training
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1140_5_QDI_CLC_V22_16x9_Large-1200px_58739.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20231019T110000
DTEND;TZID=UTC:20231019T120000
DTSTAMP:20260410T234053
CREATED:20230912T164135Z
LAST-MODIFIED:20241024T182938Z
UID:10000684-1697713200-1697716800@staging.digitalinsights.supremeclients.com
SUMMARY:A breakthrough for rare disease: Completing the Clinical exome gap!
DESCRIPTION:In its latest release\, QCI Interpret for Hereditary extends its market-leading content with further advancements in Artificial Intelligence (AI) for enhanced capabilities in clinical exome NGS testing. Now\, with the addition of AI-derived literature references for rare disease genes\, QCI Interpret provides complete exome coverage\, on top of the existing unrivalled manually curated content and bibliography. \nIn this webinar\, we will demonstrate how QCI Interpret is expanding its literature coverage enabling easy and efficient variant filtering workflow\, based on bibliography and on patient’s phenotype. This new feature provides greater control over bibliography context\, allowing users to only look at publications where the causative variant is associated with a specific disease. In addition\, the release provides AI-enhanced phenotype-driven ranking. Using this approach that has been trained using thousands of solved cases\, QCI Interpret for Hereditary Diseases provides superior overall candidate ranking for causative variants in rare diseases. The new variant-ranking approach is enhanced by taking into account additional variant related variables supported also by AI\, as well as the patient’s symptoms\, and all of the manually curated literature in the QIAGEN Knowledge Base to give the best possible chance of reaching an accurate diagnosis. \nLearning objectives: \n\nLearn about QCI Interpret’ s new AI bibliography content providing expanded clinical exome coverage\, due to the combination of the AI-derived literature references with QIAGEN’s unrivalled manual curation.\nLearn about QCI Interpret gives users the best possible chance of reaching an accurate diagnosis by providing phenotype-driven ranking that considers the detected mutations\, the patient’s symptoms\, and all the content in the QIAGEN Knowledge Base.\nView live demonstration of unique features in QCI Interpret\, which can drastically reduce the time spent on solving a case\, resulting in faster turnaround time and an accurate assessment of a case.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/a-breakthrough-for-rare-disease-completing-the-clinical-exome-gap/
LOCATION:Virtual Global Event (Times shown in EST)
CATEGORIES:Clinical,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1327_7_QDI_QCI_Hereditary_Summit.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231024T130000
DTEND;TZID=America/New_York:20231024T143000
DTSTAMP:20260410T234053
CREATED:20230912T154214Z
LAST-MODIFIED:20241024T182936Z
UID:10000677-1698152400-1698157800@staging.digitalinsights.supremeclients.com
SUMMARY:Multi-omics (metabolomics\, proteomics\, transcriptomics) analysis using QIAGEN Ingenuity Pathway Analysis
DESCRIPTION:This 90-minute training session is about how QIAGEN Ingenuity Pathway Analysis (IPA) allows visualization of molecular intricacy and variations at multiple levels such as transcriptome\, proteome\, and metabolome. Through a series of brief technical vignettes\, it is demonstrated how to: \n· Generate associations among molecular signatures obtained via integrating multi-omics data \n· Extract mechanisms from multi-omics data for precision medicine \n· Disease stratification based on multi-omics profiles \n· Map disease networks among targets and indications
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/multi-omics-metabolomics-proteomics-transcriptomics-analysis-using-qiagen-ingenuity-pathway-analysis-2-2/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1036_9_QDI_IPAviral_Gi683847570_16x9_Large-1200px_53562.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231025T093000
DTEND;TZID=Europe/Paris:20231025T103000
DTSTAMP:20260410T234053
CREATED:20230912T154758Z
LAST-MODIFIED:20241024T182936Z
UID:10000678-1698226200-1698229800@staging.digitalinsights.supremeclients.com
SUMMARY:What's new in QIAGEN IPA Fall Release 2023?
DESCRIPTION:Interested in learning about new features and functionalities that have been added to IPA lately?\nDuring this webinar\, we will highlight the updates from the QIAGEN IPA Fall Release and from previous releases from this year. Topics\, amongst others\, will be\n• Newly added findings and pathways\n• Reactome pathways\n• Artificial intelligence approves to pathways\n• More precise matches in Analysis Match\n• Cell type prediction\n• New queueing view for checking your analysis status\nBring any questions you may have and we will answer them during the webinar.\nIPA release notes are available via the following webpage: https://digitalinsights.qiagen.com/products/qiagen-ipa/latest-improvements/current-line/
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/whats-new-in-qiagen-ipa-fall-release-2023/
LOCATION:Virtual - EMEA - CET
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1269_5_QDI_QDI_IPA_0676.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231025T110000
DTEND;TZID=America/New_York:20231025T120000
DTSTAMP:20260410T234053
CREATED:20230912T155150Z
LAST-MODIFIED:20241024T182936Z
UID:10000679-1698231600-1698235200@staging.digitalinsights.supremeclients.com
SUMMARY:What's new in QIAGEN IPA Fall Release 2023?
DESCRIPTION:Interested in learning about new features and functionalities that have been added to IPA lately?\nDuring this webinar\, we will highlight the updates from the QIAGEN IPA Fall Release and from previous releases from this year. Topics\, amongst others\, will be\n• Newly added findings and pathways\n• Reactome pathways\n• Artificial intelligence approves to pathways\n• More precise matches in Analysis Match\n• Cell type prediction\n• New queueing view for checking your analysis status\nBring any questions you may have and we will answer them during the webinar.\nIPA release notes are available via the following webpage: https://digitalinsights.qiagen.com/products/qiagen-ipa/latest-improvements/current-line/
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/whats-new-in-qiagen-ipa-fall-release-2023-2/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1269_5_QDI_QDI_IPA_0676.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231025T130000
DTEND;TZID=America/New_York:20231025T140000
DTSTAMP:20260410T234053
CREATED:20230927T123320Z
LAST-MODIFIED:20241024T182942Z
UID:10000689-1698238800-1698242400@staging.digitalinsights.supremeclients.com
SUMMARY:Real-World Applications of Clinical Metagenomic Sequencing in Cancer and Infectious Disease Diagnostics
DESCRIPTION:Clinical metagenomic next-generation sequencing (mNGS)\, the comprehensive analysis of microbial and host DNA and RNA in samples from patients\, is rapidly moving from research to clinical laboratories. This emerging approach is changing the diagnosis and treatment of diseases\, with applications in a range of areas\, including oncology\, human host gene expression (transcriptomics)\, and antimicrobial infections and resistance. \nIn this webinar\, Elif Dagdan\, the director of the Center for Medical Genetics at Augusta Hospital Bochum in Bochum\, Germany\, will discuss real-world applications of using clinical mNGS to improve diagnostics of cancer and infectious diseases. The talk will also feature challenges and opportunities of using mNGS in disease diagnostics and how Dagdan’s lab uses clinical variant interpretation and reporting software from Qiagen to detect and characterize pathogenic somatic variants. \nDagdan will discuss: \nHow mNGS can be used to assess homologous recombination deficiency (HRD) status in patients with ovarian cancer.\nHow mNGS can be used to assess cell-free microbial DNA via liquid biopsy to aid in early-stage lung cancer diagnosis.\nHow mNGS can improve the accuracy and speed of infectious disease diagnostics\, with a use-case on cardiovascular infections in intensive care units.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/real-world-applications-of-clinical-metagenomic-sequencing-in-cancer-and-infectious-disease-diagnostics/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Clinical,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_9002_Genomics_EGS_gi1002000796_16x9_Large-1200px_45500.jpg
END:VEVENT
END:VCALENDAR